Therapeutic targeting of PRMT5 in homozygous MTAP-deleted cancer cells has thus been considered a promising strategy to prevent methylosome organization, selectively killing cancer cells9,10,15 (Supplementary Fig. 1). Here, PRMT5 is linked to cancer.